A double effect molecular switch leads to a novel potent negative allosteric modulator of metabotropic glutamate receptor 5

Compounds that modulate the function of G-protein-coupled receptors (GPCRs) by binding to their allosteric sites are of potential interest for the treatment of multiple CNS and non-CNS disorders. Allosteric ligands can act either as positive (PAM), negative (NAM), or silent (SAM) receptor modulators...

ver descrição completa

Detalhes bibliográficos
Autores: Gómez-Santacana, Xavier, Rovira, X., Dalton, J. A., Goudet, C., Pin, J. P., Gorostiza, P., Giraldo, J., Llebaria, Amadeu
Tipo de documento: artigo
Estado:Versión aceptada para publicación
Data de publicação:2014
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositório:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/415430
Acesso em linha:http://hdl.handle.net/10261/415430
https://api.elsevier.com/content/abstract/scopus_id/84907811678
Access Level:Acceso aberto
Palavra-chave:G-protein-coupled receptors (GPCRs)
Allosteric ligands
http://metadata.un.org/sdg/9
http://metadata.un.org/sdg/3
Ensure healthy lives and promote well-being for all at all ages
Build resilient infrastructure, promote inclusive and sustainable industrialization and foster innovation
Descrição
Resumo:Compounds that modulate the function of G-protein-coupled receptors (GPCRs) by binding to their allosteric sites are of potential interest for the treatment of multiple CNS and non-CNS disorders. Allosteric ligands can act either as positive (PAM), negative (NAM), or silent (SAM) receptor modulators and have numerous advantages over classic orthosteric compounds, including improved GPCR-subtype selectivity; the capacity to adapt to physiological conditions; and better safety profiles. Despite these benefits, allosteric modulators are difficult to design and optimize and are often prone to "molecular switching": a structural phenomenon by which very subtle chemical variations in the ligand result in unexpected changes in selectivity profiles or pharmacology, changing PAMs to NAMs or vice versa. Here, we report the discovery of a nanomolar and subtype selective NAM of metabotropic glutamate receptor 5 (mGlu<inf>5</inf>) through a targeted "double effect molecular switch" of a potent mGlu<inf>4</inf> PAM, and suggests a promising approach towards the discovery of novel mGluR allosteric modulators.